Mar 29, 2026Cardiometabolic HealthGLP-1 Drugs and PAD: Better Walking, Unproven Amputation PreventionGLP-1 drugs may improve walking in diabetes and PAD, but the headline 47% amputation reduction comes from weak observational evidence—not trials.glp-1 agonistssemaglutideliraglutideperipheral artery diseaseRead article →
Mar 21, 2026Glp1 AgonistsDo GLP-1 Drugs Raise Cancer Risk? What Trials ShowDo Ozempic, Wegovy, and Mounjaro raise cancer risk? Evidence from 48 trials and 94,245 patients finds no signal within 2–5 years.liraglutideglp-1 agoniststhyroid cancersaxendaRead article →
Mar 21, 2026Glp 1 Agonists47 GLP-1 Trials: What the Pooled Weight-Loss Result MeansA 47-trial GLP-1 meta-analysis found lower weight, BMI, and waist size—but pooled results hide major differences by drug and diabetes status.tirzepatidesemaglutideglp-1 agonistliraglutideRead article →
Mar 21, 2026Obesity DrugsObesity Drug Guidelines: What GRADE Says Actually WorksNew GRADE obesity guidelines rank tirzepatide and semaglutide highest, but indirect comparisons, lean-mass loss, cost, and access still matter.glp-1semaglutidetirzepatideweight loss drugsRead article →
Mar 13, 2026NutritionLiraglutide vs. Exercise for Weight MaintenanceA 52-week trial compared liraglutide, exercise, and both after weight loss. Did either change appetite, eating behavior, or sedentary time?liraglutideglp-1 agonistappetite suppressionweight maintenanceRead article →